Search Results - "Preece, Natasha"

Effect of social capital, social support and social network formation on the quality of life of American adults during COVID-19 by Larnyo, Ebenezer, Tettegah, Sharon, Griffin, Brianna, Nutakor, Jonathan Aseye, Preece, Natasha, Addai-Dansoh, Stephen, Dubon, Natalia, Liu, Senyuan

“…This study aims to evaluate the effect of social capital (SC), social support (SS), and social network formation (SNF) on the quality of life of American…”
Get full text

Development of Novel, Highly Potent Inhibitors of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF): Increasing Cellular Potency through Optimization of a Distal Heteroaromatic Group by Suijkerbuijk, Bart M. J. M, Niculescu-Duvaz, Ion, Gaulon, Catherine, Dijkstra, Harmen P, Niculescu-Duvaz, Dan, Ménard, Delphine, Zambon, Alfonso, Nourry, Arnaud, Davies, Lawrence, Manne, Helen A, Friedlos, Frank, Ogilvie, Lesley M, Hedley, Douglas, Lopes, Filipa, Preece, Natasha P. U, Moreno-Farre, Javier, Raynaud, Florence I, Kirk, Ruth, Whittaker, Steven, Marais, Richard, Springer, Caroline J

“…We describe the design, synthesis, and optimization of a series of new inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF), a kinase whose…”
Get full text

A Novel, Selective, and Efficacious Nanomolar Pyridopyrazinone Inhibitor of V600EBRAF by WHITTAKER, Steven, MENARD, Delphine, LAMBROS, Maryou, REIS-FILHO, Jorge S, MARAIS, Richard, SPRINGER, Caroline J, KIRK, Ruth, OGILVIE, Lesley, HEDLEY, Douglas, ZAMBON, Alfonso, LOPES, Filipa, PREECE, Natasha, MANNE, Helen, RANA, Sareena

“…Oncogenic BRAF is a critical driver of proliferation and survival and is thus a validated therapeutic target in cancer. We have developed a potent inhibitor,…”
Get full text

RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors by Su, Fei, Viros, Amaya, Milagre, Carla, Trunzer, Kerstin, Bollag, Gideon, Spleiss, Olivia, Reis-Filho, Jorge S, Kong, Xiangju, Koya, Richard C, Flaherty, Keith T, Chapman, Paul B, Kim, Min Jung, Hayward, Robert, Martin, Matthew, Yang, Hong, Wang, Qiongqing, Hilton, Holly, Hang, Julie S, Noe, Johannes, Lambros, Maryou, Geyer, Felipe, Dhomen, Nathalie, Niculescu-Duvaz, Dan, Niculescu-Duvaz, Ion, Zambon, Alfonso, Preece, Natasha, Robert, Lídia, Otte, Nicholas J, Mok, Stephen, Kee, Damien, Ma, Yan, Zhang, Chao, Habets, Gaston, Burton, Elizabeth A, Wong, Bernice, Nguyen, Hoa, Kockx, Mark, Andries, Luc, Lestini, Brian, Nolop, Keith B, Lee, Richard J, Joe, Andrew K, Troy, James L, Gonzalez, Rene, Hutson, Thomas E, Puzanov, Igor, Chmielowski, Bartosz, Springer, Caroline J, McArthur, Grant A, Sosman, Jeffrey A, Lo, Roger S, Ribas, Antoni, Marais, Richard

“…Patients with melanoma who are treated with a BRAF inhibitor have a high incidence of keratoacanthomas. Most of the tumors have oncogenic mutations in HRAS…”
Get full text

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma by Girotti, Maria Romina, Lopes, Filipa, Preece, Natasha, Niculescu-Duvaz, Dan, Zambon, Alfonso, Davies, Lawrence, Whittaker, Steven, Saturno, Grazia, Viros, Amaya, Pedersen, Malin, Suijkerbuijk, Bart M.J.M., Menard, Delphine, McLeary, Robert, Johnson, Louise, Fish, Laura, Ejiama, Sarah, Sanchez-Laorden, Berta, Hohloch, Juliane, Carragher, Neil, Macleod, Kenneth, Ashton, Garry, Marusiak, Anna A., Fusi, Alberto, Brognard, John, Frame, Margaret, Lorigan, Paul, Marais, Richard, Springer, Caroline

“…BRAF and MEK inhibitors are effective in BRAF mutant melanoma, but most patients eventually relapse with acquired resistance, and others present intrinsic…”
Get full text

Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma by Bridgeman, Victoria L, Wan, Elaine, Foo, Shane, Nathan, Mark R, Welti, Jonathan C, Frentzas, Sophia, Vermeulen, Peter B, Preece, Natasha, Springer, Caroline J, Powles, Thomas, Nathan, Paul D, Larkin, James, Gore, Martin, Vasudev, Naveen S, Reynolds, Andrew R

“…Sunitinib and pazopanib are antiangiogenic tyrosine kinase inhibitors (TKI) used to treat metastatic renal cell carcinoma (RCC). However, the ability of these…”
Get full text

Contrasting effects of sunitinib within in vivo models of metastasis by Welti, Jonathan C., Powles, Thomas, Foo, Shane, Gourlaouen, Morgane, Preece, Natasha, Foster, Julie, Frentzas, Sophia, Bird, Demelza, Sharpe, Kevin, van Weverwijk, Antoinette, Robertson, David, Soffe, Julie, Erler, Janine T., Pili, Roberto, Springer, Caroline J., Mather, Stephen J., Reynolds, Andrew R.

“…Sunitinib is a potent and clinically approved tyrosine kinase inhibitor that can suppress tumour growth by inhibiting angiogenesis. However, conflicting data…”
Get full text

Abstract LB-212: Therapeutic efficacy of the paradox-breaking panRAF and SRC drug CCT3833/BAL3833 in KRAS-driven cancer models by Saturno, Grazia, Lopes, Filipa, Girotti, Maria Romina, Niculescu-Duvaz, Ion, Niculescu-Duvaz, Dan, Zambon, Alfonso, Davies, Lawrence, Johnson, Louise, Preece, Natasha, Viros, Amaya, Pedersen, Malin, McLeary, Robert, Knight, Ruth, Lee, Rebecca, Holovanchuk, Denys, Lorigan, Paul, Dhomen, Nathalie, Marais, Richard, Springer, Caroline

“…Abstract KRAS is mutated in ∼80% of pancreatic ductal adenocarcinoma (PDAC), ∼35% of colorectal cancer (CRC) and ∼20% of non-small-cell lung cancer (NSCLC)…”
Get full text

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma by Girotti, Maria Romina, Lopes, Filipa, Preece, Natasha, Niculescu-Duvaz, Dan, Zambon, Alfonso, Davies, Lawrence, Whittaker, Steven, Saturno, Grazia, Viros, Amaya, Pedersen, Malin, Suijkerbuijk, Bart M.J.M., Menard, Delphine, McLeary, Robert, Johnson, Louise, Fish, Laura, Ejiama, Sarah, Sanchez-Laorden, Berta, Hohloch, Juliane, Carragher, Neil, Macleod, Kenneth, Ashton, Garry, Marusiak, Anna A., Fusi, Alberto, Brognard, John, Frame, Margaret, Lorigan, Paul, Marais, Richard, Springer, Caroline

Get full text

Novel Hinge Binder Improves Activity and Pharmacokinetic Properties of BRAF Inhibitors by Zambon, Alfonso, Ménard, Delphine, Suijkerbuijk, Bart M. J. M, Niculescu-Duvaz, Ion, Whittaker, Steven, Niculescu-Duvaz, Dan, Nourry, Arnaud, Davies, Lawrence, Manne, Helen A, Lopes, Filipa, Preece, Natasha, Hedley, Douglas, Ogilvie, Lesley M, Kirk, Ruth, Marais, Richard, Springer, Caroline J

“…Mutated BRAF serine/threonine kinase is implicated in several types of cancer, with particularly high frequency in melanoma and colorectal carcinoma. We…”
Get full text

Abstract 3704: Novel panRAF inhibitors active in melanomas that are resistant to BRAF-selective, or BRAF-selective/MEK inhibitor combinations by Girotti, Maria R., Lopes, Filipa, Preece, Natasha, Niculescu-Duvaz, Dan, Zambon, Alfonso, Davies, Lawrence, Whittaker, Steven, Saturno, Grazia, Viros, Amaya, Pedersen, Malin, Suijkerbuijk, Bart MJM, Menard, Delphine, Mcleary, Robert, Johnson, Louise, Fish, Laura, Ejiama, Sarah, Sanchez-Laorden, Berta, Carragher, Neil, Macleod, Kenneth, Ashton, Garry, Marusiak, Anna, Fusi, Alberto, Brognard, John, Frame, Margaret, Lorigan, Paul, Springer, Caroline J., Marais, Richard

“…Abstract The protein kinase BRAF is mutated ∼40% of human melanomas. BRAF is a component of the RAS/RAF/MEK/ERK pathway and BRAF or MEK inhibitors increase…”
Get full text